Enhanced surface-bound biological activity using a nanospring platform
Enhanced surface-bound biological activity using a nanospring platform
批准号:
8059213
负责人:
R Garth Sasser
金额:
$15.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-25 至 2012-06-30
关键词:
Amino AcidsAntibodiesAntigensAreaBacterial InfectionsBasic ScienceBindingBiocompatible MaterialsBiologicalBiological AssayBiological MarkersBiological ProductsBioreactorsCapsid ProteinsCell Culture TechniquesCharacteristicsChemicalsChemistryChlamydiaCommunicable DiseasesComplexDepositionDetectionDevelopmentDiagnosisDiagnosticDiscriminationDiseaseDisease OutbreaksDisease ProgressionElectronicsEnzyme-Linked Immunosorbent AssayEquipmentFluorescenceFoodFundingGlassGoalsGrowthHIVHealthHepatitis BHepatitis CHourHumanHuman PapillomavirusImmunoassayImmunoglobulin GInterleukin-2LabelLasersMeasuresMedicalMedical ResearchMicrofabricationMicrofluidicsMicrospheresMiniaturizationMonitorMusNamesOrganic ChemistryOutcomePharmaceutical PreparationsPharmacologic SubstancePhaseProceduresProductionProteinsProtocols documentationReactionReagentReflex Sympathetic DystrophyRunningSamplingScreening procedureSensitivity and SpecificitySexually Transmitted DiseasesSilicon DioxideSiteSolidSurfaceSurface AntigensSystemTechniquesTechnologyTestingTimeToxinTransfusionTumor TissueVeterinary MedicineViral VaccinesVirusVirus Diseasesantigen antibody bindingantigen bindingbasechemotherapycostcytokinedensitydisease diagnosisflexibilityimprovedinstrumentationpathogenphase 1 studysurface coatingtwo-dimensionaluser-friendlyvaccine developmentviral detection
中文摘要
描述(由申请人提供):该项目的长期商业目标是开发一种快速(分钟),敏感,廉价的基于纳米弹簧(NS)的生物平台,由于在小二维足迹中具有高活性的生物表面积,因此不需要昂贵,复杂的仪器来获得结果。目前的多重ELISA分析仅限于抗原或抗体包被珠,这需要微流体通道中的激光检测系统,或基于电化学发光的分析,设备成本高,复杂的电子芯片抗体捕获平台。本项目的长期具体目标是:1)确定NS结合抗体的负载能力和生物活性。(第一阶段);2)基于第一阶段开发的协议评估抗原下降和捕获(三明治)格式;3)开发一种多重ELISA格式,能够对多个样品进行快速、同时分析;4)评估纳米弹簧平台“小型化”检测的潜力;5)确定纳米弹簧增强多种其他生物制剂活性的能力。从几个不同的角度来看,快速执行多重ELISA检测的能力具有相关性。除了能够测定用于疾病诊断、监测人类疾病进展或治疗程序的几种不同生物标志物之外,多重测定法在兽医中的细菌和病毒疾病检测和诊断以及药物和毒素筛选方面也有实际需求。将其他生物活性分子附着在NS上的能力在开发更小、更高效的生物反应器方面具有实用价值,可用于药物和制药生产、废水处理和细胞培养中的组织生长。在第一阶段,我们建议使用二氧化硅纳米弹簧作为固相,用于捕获抗体或抗原的涂层,并确定抗体和抗原结合的最大容量,以及与目前标准ELISA检测中使用的材料(即微滴板)相比,这些分子的最大活性。在这些研究中,NS将沉积在玻璃微珠的支撑介质上。我们将研究纳米弹簧沉积的密度作为被包被蛋白活性的函数。由于生物材料的表面积急剧增加,可用于涂层的材料种类繁多,易于涂层,使用NS的成本低,因此NS具有明显的优势。由于可用于结合的大表面积,我们预计可以增加分析的灵敏度,同时减少分析的足迹,从标准的96孔格式到384或1536孔或阵列格式。这种“小型化”将有效减少所需样品和试剂的体积,从而将分析时间从几小时减少到几分钟。
英文摘要
DESCRIPTION (provided by applicant): The long-term commercial objective of this project is to develop a rapid (minutes), sensitive, inexpensive nanospring-based (NS) biological platform that does not require expensive, complex instrumentation for obtaining results due to the highly active biological surface area in a small two-dimensional footprint. Current multiplex ELISA analysis is limited to antigen- or antibody-coated beads which require laser detection systems in microfluidic channels, or electrochemilumiscent-based assays with high equipment costs and complex electronic chip antibody-capture platforms. The long-term specific aims of this project are to: 1) to determine loading capacity and biological activity of NS bound antibodies. (Phase I); 2) evaluate both antigen-down and capture (sandwich) formats based on the protocols developed in Phase I; 3) develop a multiplex ELISA format that is capable of performing rapid, simultaneous analyses on multiple samples; 4) evaluate the potential of the nanospring platform for "miniaturization" of the assay; 5) determine the ability of nanosprings to enhance the activity of a wide variety of other biological agents. The ability to rapidly perform multiplex ELISA assays has relevance from several different perspectives. Beyond the ability to assay for several different biomarkers which are used in disease diagnosis, monitoring disease progression or treatment procedures in humans, multiplex assays have a demonstrated need in bacterial and viral disease detection and diagnosis in veterinary medicine, and drug and toxin screening. The ability to attach other bioreactive molecules onto NS has utility in the development of smaller and more efficient bioreactors for drug and pharmaceutical production, wasterwater treatment, and tissue growth in cell culture. For Phase I we propose to use silica nanosprings as the solid- phase for the coating of capture antibodies or antigens, and to determine the maximum capacity of antibody and antigen binding, and maximum activity of these molecules as compared to currently available materials used in standard ELISA assays (i.e microtiter plates). For these studies, NS will be deposited on a support medium of glass microbeads. We will investigate both the density of nanospring deposition as a function of activity of the coated proteins. NS offer a distinct advantage over these other materials due to the dramatic increase in the surface area available for biological materials, the wide variety of materials available for coating and the ease at which these materials can be coated, the low cost of using NS. As a result of the large surface area available for binding, we anticipate that the sensitivity of the assay can be increased while reducing the footprint of the assay from a standard 96-well format to a 384- or 1536-well or array format. This "miniaturization" will effectively reduce the volume of sample and reagents needed thus reducing the time of the assay from hours to minutes.
PUBLIC HEALTH RELEVANCE: A greater available surface area afforded by nanosprings (250 fold) will facilitate the binding of multiple capture proteins and/or antibodies, allowing for a single assay test-well to be used in the detection of multiple chemical compounds (multiplex immunoassay). Tests may be completed in a shorter time (minutes rather than hours), on a smaller test platform and on the site of examination and will be invaluable in a variety of health-related applications: viral detection and vaccine development; multiple detection of pro-inflamatory cytokines in multi- symptomatic diseases (e.g. reflex sympathetic dystrophy); the detection of angiogenic cytokines in human tumor tissue (allowing for the selection of specific chemotherapeutic drugs); detection and discrimination of hepatitis B and C, and HIV type-1 viruses (common transfusion-transmitted pathogens); combined detection of Chlamydia. trachomatis and human papillomaviruses (two asymptomatic, sexually transmitted diseases); to evaluate the changes in specific biomarkers as a predictive indicator of positive-outcome chemotherapy; or to detect food pathogens and toxins prior to distribution of contaminated products, to name a few.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金